Juvenile Dermatomyositis

As 2024 comes to a close, Healio has assembled this year’s most-read pediatric dermatology articles.

The FDA has granted rare pediatric disease designation to Descartes-08, an autologous mRNA cell therapy, for the treatment of juvenile dermatomyositis, Cartesian Therapeutics announced in a press release.

Conventional memory B cells with low CXCR5 levels and CXCR5 T-helper 2 memory cells are potential biomarkers of juvenile dermatomyositis disease activity, according to data published in Arthritis & Rheumatology.

Juvenile dermatomyositis challenges rheumatologists to accurately assess not only the skin but also pulmonary and cardiac function in making a diagnosis, according to a speaker at the 2021 Rheumatology Nurses Society annual conference.

Skin disease is more active than muscle disease in juvenile dermatomyositis and should be treated early and aggressively to limit its severity, according to a study.